Wegovy Pill Accelerates Novo Nordisk’s Bid to Regain Market Share from Eli Lilly
Novo Nordisk’s Wegovy pill is poised to help the Danish pharmaceutical giant reclaim its market share from Eli Lilly in the competitive weight-loss drug sector. This new oral medication has launched at an unprecedented pace, marking a significant milestone in the global weight-loss market.
Rapid Approval and Prescription Surge
The Wegovy pill received approval from U.S. regulators in late December. By the end of February, over 300,000 prescriptions had been issued by American doctors, according to IQVIA data. Currently, the United States is the only country where Wegovy is available, representing a critical opportunity for Novo Nordisk to enhance its market position. The company, known for its Ozempic brand, had previously dominated the weight-loss drug market until approximately 18 months ago.
Since then, Novo has faced challenges, losing ground to Eli Lilly in the key U.S. market. The company’s shares have suffered due to increased competition, disappointing clinical outcomes, and concerns about its product pipeline and future profitability. However, the strong initial demand for Wegovy, which demonstrated an average weight loss of 17% in clinical trials, presents a chance for Novo to regain its former status.
Historic Launch and Marketing Strategy
Brian Lian, CEO of Viking Therapeutics, characterized the Wegovy launch as “the fastest drug launch in history.” The rollout was supported by an extensive multimedia advertising campaign, including Novo’s first-ever commercial during the Super Bowl. Lian noted that this reflects the substantial demand for weight-loss treatments, drawing parallels to the competition between tech giants Apple and Samsung.
While Eli Lilly currently leads the market, the focus is shifting toward oral medications. The introduction of Wegovy pills is significant, as previous weight-loss drugs required injections. Although Novo’s product has reached U.S. consumers first, Lilly’s Orforglipron, which achieved an average weight loss of 12.4% in trials, is anticipated to receive regulatory approval in April.
Market Dynamics and Competitive Landscape
Once the most valuable company in Europe by market capitalization, Novo Nordisk has seen its shares decline by over 50% in the past year, now trading at less than two-thirds of their peak value in June 2024. In contrast, Eli Lilly has emerged as a trillion-dollar company, bolstered by the success of its weight-loss medications. Following challenges in the 2010s due to patent expirations, Lilly’s Tirzepatide—marketed as Zepbound for weight loss and Mounjaro for diabetes—has become the second-largest drug globally by sales.
Evan Seigerman, an analyst at BMO Capital Markets, remarked that the successful U.S. launch of Wegovy indicates that Novo has “learned from its mistakes.” The company has improved its supply chain and production capacity, and it is now selling the drug directly to consumers, bypassing pharmacy benefit managers. Seigerman emphasized the rapid availability and popularity of Wegovy, noting that Novo has a limited window to regain market share before Lilly’s Orforglipron is approved.
Challenges Ahead for Novo Nordisk
Despite the promising launch, Novo Nordisk faces several hurdles. The active ingredient in Wegovy and Ozempic, semaglutide, is set to lose patent protection in several countries, including India, China, Brazil, and Turkey, this year. The company has already lost patent protection in Canada, a major market for weight-loss and diabetes drugs.
In Brazil, 11 manufacturers are seeking regulatory approval to produce generic weight-loss medications following the expiration of Novo’s patent next month. In India, around 40 local companies are expected to enter the market, potentially halving prices for weight-loss drugs.
Prescription Trends and Pricing Strategy
Wegovy pills must be taken on an empty stomach, requiring patients to wait at least 30 minutes before consuming food or other oral medications. Mike Doustdar, CEO at Novo, acknowledged this limitation but stated that it has not significantly deterred patients, who often find ways to accommodate the waiting period.
Prescription data reveals Eli Lilly’s dominance in the U.S. market, with 1.4 million prescriptions for its weight-loss drugs, including diabetes treatments, by the end of February. In comparison, Novo’s weight-loss drugs, including both pills and injections, accounted for 924,000 prescriptions, not including online sales. Doustdar reported that over 600,000 prescriptions for Wegovy pills have been issued since their launch.
Michael Nedelcovych, an equity research analyst at TD Cowen, suggested that Wegovy pills could provide Novo with a competitive edge. He noted that if Novo successfully navigates the launch phase and expands market access, it could enhance its competitive position. Price remains a critical factor; some patients have switched from Lilly’s injections to Wegovy due to lower costs.
Novo is currently pricing the lower doses of Wegovy at $149 per month in the U.S., with a planned increase to $199 for the 4 mg dose in April. Patients with health insurance may pay as little as $25 per month for these lower doses. Higher doses, at 9 mg and 25 mg, are priced at $299 per month. In contrast, weight-loss injections can cost up to $1,300 per month without insurance. Eli Lilly has announced it will offer Orforglipron for $149 per month, with higher doses reaching up to $399. Pricing strategies will likely influence the market penetration of these oral medications, with indications that they are attracting new patients rather than merely converting existing injection users.
As reported by www.emirates247.com.
Published on 2026-03-14 19:23:00 • By Editorial Desk
Follow the latest developments and breaking updates in the Latest News section.
